Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study-Reference-Cited by-同舟云学术

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study

Published:2014 Issue:1 Volume:13 Page:65
ISSN:1475-2840
Container-title:Cardiovascular Diabetology
language:en
Short-container-title:Cardiovasc Diabetol

Author:

Kaku Kohei,Watada Hirotaka,Iwamoto Yasuhiko,Utsunomiya Kazunori,Terauchi Yasuo,Tobe Kazuyuki,Tanizawa Yukio,Araki Eiichi,Ueda Masamichi,Suganami Hideki,Watanabe Daisuke,

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism

Reference12 articles.

1. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

2. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, 12‐week study

3. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

4. Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

5. Glucagon-like peptide-1 analogues for type 2 diabetes

Cited by 169 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of canagliflozin and teneligliptin on energy intake and body weight in Japanese patients with Type 2 diabetes: a subanalysis of the CANTABILE study;BMC Endocrine Disorders;2024-08-19

2. Effects of Switching From Another Sodium-Glucose Cotransporter 2 Inhibitor to Tofogliflozin on Nocturia in Patients With Type 2 Diabetes;Cureus;2024-04-30

3. Impact of SGLT-2 inhibitors on modifiable cardiovascular risk factors in Romanian patients with type 2 diabetes mellitus;Diabetology & Metabolic Syndrome;2024-04-16

4. The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials;Diabetes, Obesity and Metabolism;2024-04-11

5. Changes in serum levels of liver-related parameters, uric acid, and hemoglobin in patients with type 2 diabetes mellitus under treatment with tofogliflozin—a post-hoc analysis of the UTOPIA study;Diabetology International;2024-02-10